Dexmedetomidine on Intraoperative Somatosensory and Motor Evoked Potential Monitoring During Neurosurgery in Pediatric Patients
Launched by OREGON HEALTH AND SCIENCE UNIVERSITY · Jan 13, 2012
Trial Information
Current as of July 22, 2025
Completed
Keywords
ClinConnect Summary
Somatosensory evoked potential (SSEP) and motor evoked potential (MEP) have become an integral component in intraoperative care of patients and have resulted in a high degree of sensitivity in predicting neurologic outcomes. According to Padberg, Nuwer and Ecker ,SSEP and MEP monitoring allows surgical interventions to occur early and thus decreases the incidence of postoperative neurologic deficits.
These measurements are done during surgery under general anesthesia and it is known that anesthetic agents have a dose-dependent adverse effect on the ability to record evoked potential respon...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Pediatric patients between 2 and 12 years old
- • Undergoing neurosurgery and
- • Requiring SSEP/ MEP measurements
- Exclusion Criteria:
- • Patients younger than 2 and older than 12 years
- • Patients with known bradyarrhythmias
- • Patients with severe liver disease
- • Conditions that may alter reading, e.g. neuromuscular diseases
About Oregon Health And Science University
Oregon Health and Science University (OHSU) is a leading academic medical center dedicated to advancing health through research, education, and patient care. As a prominent sponsor of clinical trials, OHSU leverages its extensive expertise in various medical fields to facilitate innovative research aimed at improving patient outcomes. The institution is committed to ethical standards and rigorous scientific methodologies, fostering collaborations that enhance the development of new therapies and interventions. With a focus on translating research discoveries into clinical practice, OHSU plays a pivotal role in shaping the future of healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Portland, Oregon, United States
Patients applied
Trial Officials
Heike Gries, MD, PhD
Principal Investigator
Oregon Health and Science University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials